Perception towards COVID-19 vaccine. by Adaobi Uchenna Mosanya (20384248)

“…The modal age range was 18–24 years accounting for 814 (71.2%) of the participants. A total of 577 (50.5%) participants demonstrated a good level of knowledge while 685 (59.9%) showed a positive perception of the COVID-19 vaccine. …”

The level of knowledge of the COVID-19 vaccine. by Adaobi Uchenna Mosanya (20384248)

“…The modal age range was 18–24 years accounting for 814 (71.2%) of the participants. A total of 577 (50.5%) participants demonstrated a good level of knowledge while 685 (59.9%) showed a positive perception of the COVID-19 vaccine. …”

Data_Sheet_1_Temporary Salt Lakes: Ecosystem Services Shift in a Ramsar Site Over a 50-Year Period.DOCX by Ioanna Ioannidou (11034120)

2‑Aminobenzoxazole Derivatives as Potent Inhibitors of the Sphingosine-1-Phosphate Transporter Spinster Homolog 2 (Spns2) by Ariel L. Burgio (15069256)

“…To develop more potent compounds, we initiated a structure–activity relationship study that identified 2-aminobenzoxazole as a viable scaffold. …”

Pharmacological characterization of WT BMP9 and A347E variant <i>in vitro</i> and <i>in vivo.</i> by Tobias G. Schips (21799838)

Design and Synthesis of Novel Spiro Derivatives as Potent and Reversible Monoacylglycerol Lipase (MAGL) Inhibitors: Bioisosteric Transformation from 3‑Oxo-3,4-dihydro‑2<i>H</i>‑ben... by Shuhei Ikeda (2380180)

“…Optimization of the left hand side afforded <b>4f</b> as a promising reversible MAGL inhibitor, which showed potent in vitro MAGL inhibitory activity (IC₅₀ 6.2 nM), good oral absorption, blood–brain barrier penetration, and significant pharmacodynamic changes (2-arachidonoylglycerol increase and arachidonic acid decrease) at 0.3–10 mg/kg, po. in mice.…”

Global Aridity Index and Potential Evapotranspiration (ET0) Database: Version 3.1 by Robert Zomer (12796235)

TUDCA improves weight gain and alveolar formation in HOX rat pups. by Kirkwood A. Pritchard Jr. (13449794)

“…The survival rate has a trend of improvement by TUDCA (Log-rank test for trend, p = 0.02). …”

Barriers to meeting fluid intake guidelines (<i>N</i> = 137). by Abigail M. Pauley (18516295)

Participant demographics of pregnant women (<i>N</i> = 137). by Abigail M. Pauley (18516295)

Responses to Hydration Knowledge, Behaviors, and Digital Tool Feasibility Questions (<i>N</i> = 135). by Abigail M. Pauley (18516295)

Period of influence of each daily variable on the pod status change, from healthy to diseased with no signs of sporulation, 40 to 50 days after tagging. by Mariela E. Leandro-Muñoz (4487608)

N-acetyl-lysyltyrosylcysteine-amide (KYC) attenuates ER stress in HOX and Tun-treated neonatal lungs with improved alveolar formation. by Kirkwood A. Pritchard Jr. (13449794)

“…<p>(<b>A</b>) All ER stress markers in the HOX lungs (P-PERK 0.4±0.2-fold; P-IRE1α 0.4±0.2-fold; GRP78 0.5±0.1-fold; cleaved ATF6 0.3±0.2-fold; spliced XBP1 0.4±0.4-fold; CHOP 0.4±0.3-fold) decrease significantly by KYC (n = 12, p<0.05, 6 for each sex). …”

image2_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…In RAW264.7 cells and bone marrow monocytes (BMMCs), myostatin activates the expression of the II type receptor ActR II B. Here, we report that myostatin significantly promoted RANKL/M-CSF-induced osteoclastogenesis and activated NF-κB and MAPK pathways in vitro via the Ccdc50 gene. …”

presentation1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.pptx by Xin Zhi (1829224)

“…In RAW264.7 cells and bone marrow monocytes (BMMCs), myostatin activates the expression of the II type receptor ActR II B. Here, we report that myostatin significantly promoted RANKL/M-CSF-induced osteoclastogenesis and activated NF-κB and MAPK pathways in vitro via the Ccdc50 gene. …”

image3_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…In RAW264.7 cells and bone marrow monocytes (BMMCs), myostatin activates the expression of the II type receptor ActR II B. Here, we report that myostatin significantly promoted RANKL/M-CSF-induced osteoclastogenesis and activated NF-κB and MAPK pathways in vitro via the Ccdc50 gene. …”

presentation1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.pptx by Xin Zhi (1829224)

“…In RAW264.7 cells and bone marrow monocytes (BMMCs), myostatin activates the expression of the II type receptor ActR II B. Here, we report that myostatin significantly promoted RANKL/M-CSF-induced osteoclastogenesis and activated NF-κB and MAPK pathways in vitro via the Ccdc50 gene. …”

presentation1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.pptx by Xin Zhi (1829224)

“…In RAW264.7 cells and bone marrow monocytes (BMMCs), myostatin activates the expression of the II type receptor ActR II B. Here, we report that myostatin significantly promoted RANKL/M-CSF-induced osteoclastogenesis and activated NF-κB and MAPK pathways in vitro via the Ccdc50 gene. …”

image1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…In RAW264.7 cells and bone marrow monocytes (BMMCs), myostatin activates the expression of the II type receptor ActR II B. Here, we report that myostatin significantly promoted RANKL/M-CSF-induced osteoclastogenesis and activated NF-κB and MAPK pathways in vitro via the Ccdc50 gene. …”

image1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…In RAW264.7 cells and bone marrow monocytes (BMMCs), myostatin activates the expression of the II type receptor ActR II B. Here, we report that myostatin significantly promoted RANKL/M-CSF-induced osteoclastogenesis and activated NF-κB and MAPK pathways in vitro via the Ccdc50 gene. …”